The human and economic burden of poststroke spasticity and muscle overactivity

Journal of Clinical Outcomes Management

Volumn 18, Issue 1, 2011, Pages 34-44

  Esquenazi, Alberto ^a  

^a Gait and Motion Analysis Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A; DANTROLENE; DIAZEPAM; PLACEBO; TIZANIDINE; TRIHEXYPHENIDYL;

ABSENTEEISM; ASHWORTH SCALE; CAREGIVER BURDEN; CLINICAL ASSESSMENT; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DAILY LIFE ACTIVITY; DISABILITY ASSESSMENT SCALE; DRUG COST; ECONOMIC ASPECT; FALL RISK; FALLING; FRACTURE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; GAIT; HEALTH CARE COST; HEALTH INSURANCE; HEMIPARESIS; HIP FRACTURE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HOSPITAL COST; HUMAN; JOINT FUNCTION; MODIFIED ASHWORTH SCALE; MOTOR DYSFUNCTION; MOTOR NEURON DISEASE; MUSCLE CONTRACTURE; MUSCLE OVERACTIVITY; MUSCLE TONE; PHYSIOTHERAPY; POSTSTROKE SPASTICITY; QUALITY OF LIFE; RANGE OF MOTION; RATING SCALE; REVIEW; SPASTICITY; STROKE; STROKE ADAPTED SICKNESS IMPACT PROFILE; STROKE PATIENT; SURVIVOR; TARDIEU SCALE; UNEMPLOYMENT;

EID: 79952091089     PISSN: 10796533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update. A report from the American Heart Association. Circulation 2010;121:e46-e215.
2. National Institute of Neurological Disorders and Stroke. Stroke: Hope through research. Available at www.ninds.nih.gov/disorders/stroke/detail-stroke. htm.
3. Esquenazi A, Mayer NH. Instrumented assessment of muscle overactivity and spasticity with dynamic polyelectromyographic and motion analysis for treatment planning. Am J Phys Med Rehabil 2004;83:S19-S29. (Pubitemid 39281265)
4. Mayer NH, Esquenazi A, Childers MK. Common patterns of clinical motor dysfunction. Muscle Nerve Suppl 1997;6: S21-S35. (Pubitemid 128753037)
5. Mayer N, Esquenazi A. Upper limb skin and musculoskeletal consequences of the upper motor neuron syndrome. In: Jankovic J, Albanese A, Atassi MZ, et al (editors). Botulinum toxin, therapeutic clinical practice & science. Philadelphia: Elsevier; 2009:131-47.
6. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP (editors). Spasticity: disordered motor control. Miami: Year Book Medical Publishers; 1980:485-94.
7. Lundström E, Smits A, Borg J, Terént A. Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event. Stroke 2010;41:319-24.
8. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and career burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000;69:217-21. (Pubitemid 30466027)
9. Mayer NH, Esquenazi A. Muscle overactivity and movement dysfunction in the upper motoneuron syndrome. Phys Med Rehabil Clin N Am 2003;14:855-83, vii-viii.
10. Mizrahi EM, Angel RW. Impairment of voluntary movement by spasticity. Ann Neurol 1979;5:594-5. (Pubitemid 9183604)
11. Esquenazi A. Falls and fractures in older post-stroke patients with spasticity: consequences and drug treatment considerations. Clin Geriatrics 2004;12:27-35.
12. Nichol MB, Shi SG, Knight TK, et al. Risk of hip or vertebral fracture in stroke survivors using antispasticity medications: a case-control study. J Outcomes Research 2006;10:1-11.
13. Soyuer F, Öztürk A. The effect of spasticity, sense and walking aids in falls of people after chronic stroke. Disabil Rehabil 2007;29:679-87. (Pubitemid 46672324)
14. Sommerfeld DK, Eek EU, Svensson AK, et al. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke 2004;35:134-9. (Pubitemid 38057606)
15. Urban PR Wolf T, Uebele M, et al. Occurence and clinical predictors of spasticity after ischemic stroke. Stroke 2010;41:2016-20.
16. Wissel J, Schelosky LD, Scott J, et al. Early development of spasticity following stroke: a prospective, observational trial. J Neurol 2010; Epub ahead of print.
17. Welmer AK, von Arbin M, Widén Holmqvist L, Sommerfeld DK. Spasticity and its association with functioning and health-related quality of life 18 months after stroke. CerebrovascDis 2006;21:247-53.
18. Watkins CL, Leathley MJ, Gregson JM, et al. Prevalence of spasticity post stroke. Clin Rehabil 2002;16:515-22.
19. Lundström E, Terént A, Borg J. Prevalence of disabling spasticity 1 year after first-ever stroke. Eur J Neurol 2008;15:533-9. (Pubitemid 351677501)
20. Bhattacharya S, Saha SP, Basu A, Das SK. A 5-year prospective study of incidence, morbidity and mortality profile of stroke in a rural community of eastern India. J Indian Med Assoc 2005;103:655-9. (Pubitemid 43822136)
21. Jones VN.The forgotten survivor [Electronic version]. Stroke Smart Magazine. Available at www.stroke.org/site/PageServer?pagename=%20SS-MAG-so2006- feature-forgot.
22. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964;192:540-2.
23. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. PhysTher 1987;67:206-7. (Pubitemid 17026064)
24. Tardieu G, Dalioz JC. [Principles of examination of stiffness in the cerebral palsied child.] Arch Fr Pediatr 1963;20:1201-9.
25. Haugh AB, Pandyan AD, Johnson GR. A systematic review of the Tardieu Scale for the measurement of spasticity. Disabil Rehabil 2006;28:899-907.
26. Pandyan AD, Hermens H, Johnson GR. Spasticity. In: Squire LR (editor). Encyclopedia of neuroscience. Oxford: Academic Press; 2009: Vol 9,153-63.
27. Brashear A, Zafonte R, Corcoran M, et al. Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil 2002;83:1349-54.
28. Urban PR Wolf T, Uebele M, et al. Prevalence and clinical predictors of spasticity after ischemic stroke. Cerebrovasc Dis 2009;27:43.
29. Dajpratham P, Kuptniratsaikul V, Kovindha A, et al. Prevalence and management of poststroke spasticity in Thai stroke patients: a multicenter study. J Med Assoc Thai 2009;92: 1354-60.
30. Esquenazi A, Kim S, Mayer N. Patient registry outcomes in spasticity (PROS) care. Presented at the 70th Annual Assembly of the American Academy of Physical Medicine and Rehabilitation, Austin, TX, 22-25 Oct 2009; poster 57.
31. Pang MY, Eng JJ. Fall-related self-efficacy, not balance and mobility performance, is related to accidental falls in chronic stroke survivors with low bone mineral density. Osteoporos Int 2008;19:919-27.
32. Ramnemark A, Nyberg L, Borssen B, et al. Fractures after stroke. Osteoporos Int 1998;8:92-5. (Pubitemid 28085490)
33. Ramnemark A, Nyberg L, Lorentzon R, et al. Progressive hemiosteoporosis on the paretic side and increased bone mineral density in the nonparetic arm the first year after severe stroke. Osteoporos Int 1999;9:269-75. (Pubitemid 29182379)
34. Braithwaite RS, Col NF, Wong JB. Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 2003;51:364-70. (Pubitemid 36348898)
35. WeMove.org. Understanding spasticity. Available at: www. wemove.org/survey/WEMOVE-Spasticity-Research-Report-6-2009.pdf.
36. McCrory P, Turner-Stokes L, Baguley IJ, et al. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes. J Rehabil Med 2009;41:536-44.
37. Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life. Qual Life Res 1999;8:209-24. (Pubitemid 29367290)
38. Stafford L, Berk M, Jackson HJ. Validity of the Hospital Anxiety and Depression Scale and Patient Health Questionnaire-9 to screen for depression in patients with coronary artery disease. Gen Hosp Psychiatry 2007;29:417-24. (Pubitemid 47410308)
39. Elovic EP, Brashear A, Kaelin D, et al. Repeated treatments with botulinum toxin type A produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil 2008;89:799-806. (Pubitemid 351602250)
40. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400. (Pubitemid 34851831)
41. Gillard PJ, Doan QV, Turkel CC, et al. Hygiene and dressing disability associated with greater caregiver time among patients with upper limb post-stroke spasticity. Presented at the 70th Annual Assembly of the American Academy of Physical Medicine and Rehabilitation, Austin (TX), 22-25 Oct 2009; poster 418.
42. Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001 ;8:559-65. (Pubitemid 35015221)
43. Collin C, Wade DT, Davies S, Home V The Barthel ADL Index: a reliability study. Int Disabil Stud 1988;10:61-3.
44. Zorowitz R, Burk CT, ErtI J, et al. Burden of caregiving for patients with spasticity due to stroke or multiple sclerosis. 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation, Seattle (WA), 4-7 Nov 2010.
45. Kaste M, Fogelholm R, Rissanen A. Economic burden of stroke and the evaluation of new therapies. Public Health 1998;112:103-12. (Pubitemid 28161901)
46. Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003;21(SuppM):43-50. (Pubitemid 36332383)
47. Elovic EP, Esquenazi A, Alter KE, et al. Chemodenervation and nerve blocks in the diagnosis and management of spasticity and muscle overactivity. Am J Phys Med Rehabil 2009; 1:842-51.
48. Esquenazi A, Mayer N, Garreta R. Influence of botulinum toxin type A treatment of elbow flexor spasticity on hemiparetic gait. Am J Phys Med Rehabil 2008;87:305-10. (Pubitemid 351450748)
49. Radensky PW, Archer JW, Dournaux SF, O'Brien CF. The estimated cost of managing focal spasticity: a physician practice patterns survey. Neurorehabil Neural Repair 2001;15:57-68. (Pubitemid 32800196)
50. Wallesch CW, Maes E, Lecomte P, Bartels 0 Cost-effectiveness of botulinum toxin type A injection in patients with spasticity following stroke: a German perspective. Eur J Neurol 1997;4: S53-S57. (Pubitemid 28000093)
51. Ward A, Roberts G, Warner J, Gillard S. Cost-effectiveness of botulinum toxin type A in the treatment of post-stroke spasticity. J Rehabil Med 2005;37:252-7. (Pubitemid 41025335)
52. Simpson DM, Gracies JM, Yablon SA, et al. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebocontrolled study. J Neurol Neurosurg Psychiatry 2009;80: 380-5.
53. Childers MK, Brashear A, Jozefczyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004;85:1063-9. (Pubitemid 38962361)
54. Esquenazi A. Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity. Eur J Neurol 2006;13(Suppl 4):27-34. (Pubitemid 44748281)
55. Esquenazi A, Novak I, Sheean G, et al. International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments-introduction. Eur J Neurol 2010;17(Suppl 2):1-8.